Page 4 - Vered Caplan News Today

The global biotech company also reported a strong rise in revenue for the first nine months of its financial year to September 30, 2021 to...

Orgenesis to host conference call today at 8:30AM ET...

A glance at some of the days highlights from the Proactive Investors US and Canada newswires

Orgenesis reports four-fold increase in revenue in 1Q as it continues to grow its POCare strategy Revenue in the three months came in at $9.4 million, up from $1.8 million in the first quarter of 2020 It identifies promising new therapies and leverages its POCare Platform to provide a pathway for them to reach and treat large numbers of patients at lowered costs Orgenesis Inc (NASDAQ:ORGS) (FRA:45O), the cell and gene therapies (CGTs) focused biotech, reported a four-fold increase i...

NA Proactive news snapshot: KWESST Micro Systems, Sassy Resources, Power REIT, Delta 9 Cannabis UPDATE … A glance at some of the days highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive KWESST Micro Systems Inc (CVE:KWE) (OTCQB:KWEMF) announced plans to hold an investor update call at 2 pm ET on Tuesday, May 11. Executive Chairman David Luxton will describe the significance of the companys acquisition of Low Energy Cartr...

NA Proactive news snapshot: KWESST Micro Systems, Sassy Resources, Power REIT, Delta 9 Cannabis UPDATE … A glance at some of the days highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive KWESST Micro Systems Inc (CVE:KWE) (OTCQB:KWEMF) announced plans to hold an investor update call at 2 pm ET on Tuesday, May 11. Executive Chairman David Luxton will describe the significance of the companys acquisition of Low Energy Cartr...

Orgenesis enters second phase of collaboration with Hospital Infantil Universitario Niño Jesús in Madrid with exclusive license to commercialize Celyvir solid tumor therapy The collaboration is focused on advancing clinical development and commercialization of the oncolytic virus-based cell therap...

Orgenesis Enters Second Phase of Collaboration with Hospital Infantil Universitario Niño Jesús in Madrid with Exclusive License to Commercialize Celyvir Solid Tumor Therapy The collaboration is focused on advancing clinical development and commercialization of the oncolytic virus-based cell therapy March 11, 2021 07:00 ET | Source: Orgenesis Inc. Orgenesis Inc. GERMANTOWN, Md., March 11, 2021 (GLOBE NEWSWIRE) -- . (NASDAQ: ORGS) (“Orgenesis” or the ...

Search jobs 10-Mar-2021 Orgenesis Mobile Processing Units and Labs (OMPULs) to be Used for Point-of-Care Production and Commercialization of Cell and Gene Therapies in Collaboration with Dong-a University Hospital and Cure Therapeutics in South Korea Orgenesis Mobile Processing Units and Labs (OMPULs) to be Used for Point-of-Care Production and Commercialization of Cell and Gene Therapies in Collaboration with Dong-a University Hospital and Cure Ther...

Share: Revenue increases 96% to $7.7 million for 2020 Projects to more than double in revenue for 2021 based on current contracts already in hand Orgenesis to host conference call today at 8:30AM ET GERMANTOWN, Md., March 09, 2021 (GLOBE NEWSWIRE) -- . (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), today reported financial results for the year ended December 31, 2020 and provided a business update...